REGENXBIO Inc.

Listed Company

RGNXCIK 0001590877NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)FY ends Dec 31

Period

FY 2025

Revenue

$170.44M

Net Income

$-193.88M

Total Assets

$453.03M

Equity

$102.73M

Shares Out

51.70M

Op. Cash Flow

$-123.96M

RGNX$9.87+13.65% · past yearDBEQ Basic

Daily closing prices

Business

REGENXBIO Inc. is a clinical-stage biotechnology company developing curative gene therapies using adeno-associated virus (AAV) vectors from its proprietary NAV Technology Platform to deliver functional genes for genetic disorders. The company's investigational gene therapies target retinal diseases (wet AMD and diabetic retinopathy via collaboration with AbbVie), neuromuscular diseases (Duchenne muscular dystrophy), and neurodegenerative diseases (MPS II and MPS I via partnership with Nippon Shinyaku). REGENXBIO operates in-house manufacturing, clinical development, and commercialization capabilities, and generates revenue through NAV Technology Platform sublicensing to third parties developing their own gene therapies, including Novartis' FDA-approved products Zolgensma and Itvisma for spinal muscular atrophy.

Summary from 10-K filed 2026-03-05

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	170	83	90	113	470
Cost of license and royalty revenues	20	34	—	—	—
Research and development	228	209	232	242	181
General and administrative	83	77	88	85	79
Credit losses (recoveries)	—	−5	0	0	−3
Impairment of long-lived assets	—	2	—	—	—
Other operating expenses	179,000	865,000	397,000	−7	333,000
Total operating expenses	332	317	358	376	310
Loss from operations	−161	−233	−268	−263	160
Interest income from licensing	83,000	174,000	25,000	342,000	719,000
Investment income	12	19	11	5	7
Interest expense	−45	−13	−7	−23	—
Total other income (expense)	−33	6	4	−18	−19
Net loss	−194	−227	−263	−280	128
Unrealized gain on available-for-sale securities, net	54,000	4	11	−13	−2
Total other comprehensive income	54,000	4	11	−13	−2
Comprehensive loss	−194	−223	−253	−293	126
Net loss per share, basic	−3.76	−4.59	−6.02	−6.5	3.01
Net loss per share, diluted	−3.76	−4.59	−6.02	−6.5	2.91
Weighted-average common shares outstanding, basic	52	50	44	43	42
Weighted-average common shares outstanding, diluted	52	50	44	43	44

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	34	58	35	97	345
Marketable securities	196	177	241	268	112
Accounts receivable	26	20	25	28	32
Prepaid expenses	12	9	15	14	19
Other current assets	13	14	20	9	10
Total current assets	281	278	335	416	519
Marketable securities	11	10	39	201	392
Accounts receivable	2	474,000	701,000	2	2
Property and equipment, net	105	118	132	142	132
Operating lease right-of-use assets	47	54	60	65	61
Restricted cash	2	2	2	2	2
Other assets	5	4	5	6	6
Total assets	453	466	574	833	1,114
Accounts payable	21	23	23	27	11
Accrued expenses and other current liabilities	38	38	50	47	76
Deferred revenue	10	115,000	148,000	2	3
Operating lease liabilities	8	8	7	6	2
Royalty monetization liabilities	40	34	—	—	—
Total current liabilities	118	103	130	130	130
Deferred revenue	19	—	—	—	—
Operating lease liabilities	65	74	82	89	85
Royalty monetization liabilities	147	25	—	—	—
Other liabilities	638,000	4	6	9	745,000
Total liabilities	350	206	262	317	350
Commitments and contingencies (Note 8)	—	—	—	—	—
Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at December 31, 2025 and 2024	—	—	—	—	—
Common stock; $0.0001 par value; 100,000 shares authorized at December 31, 2025 and 2024; 50,892 and 49,549 shares issued and outstanding at December 31, 2025 and 2024, respectively	5,000	5,000	4,000	4,000	4,000
Additional paid-in capital	1,229	1,193	1,021	973	928
Accumulated other comprehensive loss	−687,000	−741,000	−4	−15	−3
Accumulated deficit	−1,130	−932	−705	−442	−161
Total stockholders equity	103	260	312	516	764
Total liabilities and stockholders equity	453	466	574	833	1,114

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−194	−227	−263	−280	128
Stock-based compensation expense	35	38	40	41	39
Depreciation and amortization	16	16	17	13	10
Net accretion of discounts on marketable debt securities	−5	−4	687,000	5	6
Net realized gain on investments	−62,000	−7	−2	79,000	−5
Impairment of long-lived assets	—	2	—	—	—
Non-cash interest expense	13	6	−414,000	137,000	5
Other non-cash adjustments	597,000	1	319,000	231,000	−281,000
Accounts receivable	−8	10	4	5	14
Prepaid expenses	−3	5	−620,000	5	−8
Other current assets	658,000	7	−11	247,000	−7
Operating lease right-of-use assets	7	6	6	4	5
Other assets	−613,000	807,000	2	31,000	−2
Accounts payable	−2	−292,000	−3	19	−2
Accrued expenses and other current liabilities	229,000	−12	2	−26	30
Deferred revenue	29	−33,000	−2	−1	−899,000
Operating lease liabilities	−9	−8	−7	−544,000	12
Other liabilities	−3	−3	−3	8	289,000
Net cash used in operating activities	−124	−173	−218	−207	219
Purchases of marketable debt securities	−333	−190	−87	−185	−498
Maturities of marketable debt securities	319	290	285	203	170
Sales of equity securities	62,000	6	2	524,000	6
Purchases of property and equipment	−2	−2	−10	−31	−84
Net cash provided by (used in) investing activities	−16	103	191	−12	−407
Proceeds from exercise of stock options	300,000	2	2	3	4
Taxes paid related to net settlement of stock-based awards	−633,000	−910,000	−419,000	−284,000	−2,000
Proceeds from issuance of common stock under employee stock purchase plan	1	1	2	2	2
Proceeds from public offering of common stock and pre-funded warrants, net of issuance costs	—	131	—	—	—
Expenses related to at-the-market offering programs	−357,000	−323,000	—	—	—
Proceeds from issuance of royalty bond and warrants, net of transaction costs	144	—	—	—	—
Repayments under royalty monetization liabilities, net of interest	−28	−40	—	—	—
Net cash provided by financing activities	117	93	−35	−29	195
Net increase (decrease) in cash and cash equivalents and restricted cash	−23	23	−62	−248	7
Cash paid (received) for income taxes	285,000	−72,000	−142,000	12	6
Cash paid for interest under royalty monetization liabilities	32	7	—	—	—
Purchases of property and equipment in accounts payable and accrued expenses and other current liabilities	889,000	339,000	—	—	558,000
Deferred equity offering costs in accounts payable and accrued expenses and other current liabilities	153,000	222,000	—	—	—
Deferred equity offering costs reclassified	499,000	628,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is REGENXBIO Inc.'s CIK number?

REGENXBIO Inc.'s SEC CIK number is 0001590877 (1590877). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find REGENXBIO Inc.'s SEC filings?

All of REGENXBIO Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did REGENXBIO Inc. last report earnings?

REGENXBIO Inc. (RGNX) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-222768). This is REGENXBIO Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is REGENXBIO Inc.'s most recent earnings 8-K?

REGENXBIO Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-222768. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View REGENXBIO Inc.'s latest earnings 8-K →
Look up any company's CIK number →